Suzhou Haowei Biomedical Technology
A developer of vascular interventional embolization products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
* | CNY20.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Established in 2021, Suzhou Haowei Biomedical Technology Co., Ltd. is a manufacturing enterprise centered on drug delivery technology, specifically focusing on the development of vascular interventional embolization products. The company operates with a business-to-business model, serving a worldwide market that includes hospitals, clinics, and diagnostic labs.
The core of Haowei Biomedical's product line revolves around microsphere technology. Their offerings include embolic microspheres, drug-eluting microspheres, balloon-occluded microcatheters, and steerable microcatheters. These products are designed for various clinical applications, including therapeutic solutions for conditions like osteoarthritis. A key product, the UniPearls® Embolic Microsphere, has received FDA 510(k) clearance, a significant milestone demonstrating its safety and effectiveness. The company also develops sustained-release microsphere formulations for drugs such as quinacrine and risperidone, as well as materials for medical aesthetics like PLLA/PLLA-PEG microspheres.
Haowei Biomedical has established a robust research and development framework, with an in-house team of 6-10 R&D professionals who possess interdisciplinary expertise in polymer science, pharmacy, biology, and medicine. This team handles the entire product development lifecycle, from microsphere design and monomer screening to shaping, aggregation system construction, and drug release evaluation. The company's commitment to quality is underscored by its ISO 13485 certification for the design, development, production, and distribution of its sterile vascular embolic microspheres and microcatheters. Production takes place in a 3,000 to 5,000 square meter facility with five production lines. The company has formed partnerships with academic institutions like Fudan University to advance its research.
Keywords: drug delivery technology, vascular intervention, embolization products, medical devices, microspheres, embolic microspheres, drug-eluting microspheres, microcatheters, biomedical manufacturing, ISO 13485, FDA 510(k), PLLA microspheres, osteoarthritis treatment, sustained-release formulations, clinical applications, polymer science, medical aesthetics, pharmaceutical technology, therapeutic solutions, interventional radiology